| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01615809 | Invasive Pulmonary Aspergillosis|Lymphoblastic Leukaemia|Myeloblastic Leukaemia|Lymphoblastic Leukemia|Myeloblastic Leukemia | Drug: MPHOTERICIN B | Fundaci Sant Joan de Du|Ministry of Health, Spain | Phase 2 | 2011-10-01 | 2015-11-04 |
| NCT00876824 | Leishmaniasis, Visceral | Drug: Amphotericin B Lipid emulsion|Drug: Liposomal Amphotericin B | Bharat Serums and Vaccines Limited|Ministry of Science and Technology | Phase 3 | 2009-07-01 | 2011-06-01 |
| NCT00628719 | Visceral Leishmaniasis | Drug: Liposomal Amphotericin B|Drug: amphotericin B deoxycholate | Banaras Hindu University | Phase 3 | 2008-02-01 | 2009-04-02 |
| NCT02283905 | Blastomycosis | Drug: amphotericin-B|Drug: voriconazole | University of Manitoba|Pfizer | Phase 4 | 2015-06-01 | 2016-08-31 |
| NCT02025491 | Disseminated Leishmaniasis | Drug: Liposomal Amphotericin B | Hospital Universitrio Professor Edgard Santos | Phase 3 | 2011-04-01 | 2013-12-30 |
| NCT00371995 | Visceral Leishmaniasis | Drug: Liposomal amphotericin B and Miltefosine | Banaras Hindu University|Rajendra Memorial Research Institute of Medical Sciences | Phase 2 | 2007-10-01 | 2011-06-21 |
| NCT01303549 | Liver Disease|Fungal Infection | Drug: Anidulafungin|Drug: Liposomal amphotericin B | Fundacion SEIMC-GESIDA|Pfizer | Phase 4 | 2011-11-01 | 2014-05-29 |
| NCT00467883 | Zygomycosis | Drug: Liposomal Amphotericin B | Assistance Publique - Hpitaux de Paris | Phase 2 | 2007-06-01 | 2014-07-17 |
| NCT00177684 | Lung Transplantation|Fungal Infections | Drug: Amphotericin B | University of Pittsburgh|Enzon Pharmaceuticals, Inc. | Phase 3 | 2004-09-01 | 2008-12-16 |
| NCT02656797 | Leishmaniasis | Drug: Topical Amphotericin-B 0.4% liposomal gel | Soroka University Medical Center | Phase 2 | 2017-02-01 | 2016-10-13 |
| NCT00425620 | Chronic Sinusitis | Drug: SinuNase | Accentia Biopharmaceuticals | Phase 3 | 2006-12-01 | 2007-11-29 |
| NCT01032187 | Visceral Leishmaniasis | Drug: Meglumine antimoniate|Drug: Amphotericin B-deoxycholate | University of Brasilia|Ministry of Health, Brazil | Phase 4 | 2007-10-01 | 2011-03-07 |
| NCT00177710 | Lung Transplantation|Fungal Infections | Drug: Amphotericin B | University of Pittsburgh|Astellas Pharma US, Inc. | Phase 3 | 2006-01-01 | 2008-12-16 |
| NCT02136030 | Cryptococcal Meningitis | Drug: Liposomal amphotericin B|Drug: Amphotericin B-deoxycholate | TTY Biopharm | | 2011-02-01 | 2014-05-08 |
| NCT01652859 | Normal Healthy Subjects | Drug: Liposomal Amphotericin B|Drug: AmBisome | Taiwan Liposome Company | Phase 1 | 2012-02-01 | 2013-11-25 |
| NCT02629419 | Candidiasis, Chronic Mucocutaneous | Drug: Amphotericin B | Matinas BioPharma Nanotechnologies, Inc. | Phase 2 | 2015-11-01 | 2017-03-10 |
| NCT00148148 | Hematopoietic Stem Cell Transplantation|Fungus Diseases | Drug: caspofungin|Drug: liposomal amphotericin B | University Hospital Muenster|Merck Sharp & Dohme Corp.|Gilead Sciences | Phase 2 | 2004-05-01 | 2008-01-09 |
| NCT00815516 | Candidiasis | Drug: micafungin|Drug: amphotericin B deoxycholate | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc | Phase 3 | 2013-02-01 | 2015-10-12 |
| NCT01845727 | Cutaneous Leishmaniasis | Drug: Topical Amphotericin B at 3% | Drugs for Neglected Diseases | Phase 1|Phase 2 | 2014-02-01 | 2016-07-25 |
| NCT01259713 | Invasive Fungal Disease | Drug: Liposomal amphotericin B|Drug: Placebo | Gilead Sciences | Phase 3 | 2011-04-01 | 2015-04-17 |
